PET positive, PET negative, or PET peeve?

Blood

Volumn 115, Issue 4, 2010, Pages 752-753

  Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADD ON THERAPY; B CELL LYMPHOMA; CLINICAL PRACTICE; CLINICAL TRIAL; HUMAN; MEDICAL EXPERT; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NOTE; NUCLEAR MEDICINE; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 77950545063     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-244947     Document Type: Note

References (8)

1. Horning SJ, Juweid ME, Schoder H, et al. Interim positron emission tomography (PET) scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115(4):775-777.
2. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma: current status. Oncologist. 2003;8(5):438-447. (Pubitemid 37238871)
3. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101(10):3875-3876. (Pubitemid 36857861)
4. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
5. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746- 3752.
6. Kotzerke J, Guhlmann A, Moog F, Frickhofen N, Reske SN. Role of attenuation correction for fluorine-18 fluorode-oxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med. 1999; 26(1):31-38. (Pubitemid 29137736)
7. Moskowitz C, Hamlin PA, Horwitz SM, et al. Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL [abstract]. Blood. 2006;108(11): Abstract 532.
8. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578.